Body composition changes in protease inhibitor‐naive HIV‐infected patients treated with two nucleoside reverse transcriptase inhibitors
Open Access
- 1 April 2002
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 3 (2) , 85-90
- https://doi.org/10.1046/j.1468-1293.2002.00105.x
Abstract
Objectives In the era of highly active antiretroviral treatment (HAART), there are insufficient data regarding lipodystrophy syndromes in HIV‐1‐infected patients treated with regimens that do not include protease inhibitors (PIs). We studied changes in body composition in HIV‐1‐infected patients before and 2 years after starting a non‐PI‐containing antiretroviral treatment regimen. Methods We studied retrospectively the whole body dual energy X‐ray absorptiometry (DEXA) scans of 23 PI‐naive HIV‐1‐infected patients (17 males, six females), aged 37.4 ± 9.3 years with mean CD4 count 401 ± 130 cells/µL. Thirteen patients were on zidovudine (ZDV) + lamivudine (3TC) and 10 on ZDV + didanosine (ddI). Subjects were evaluated before the beginning of antiretroviral treatment and approximately 24 months later. For each patient body weight, CD4 T‐cell counts, bone mineral content (BMC), bone mineral density (BMD) and whole body as well as regional fat and lean body mass were evaluated. Results A significant decrease in BMC was observed, although the T scores remained within the normal limits. Our patients also exhibited a significant decrease in body weight due almost exclusively to fat loss, while lean mass was minimally affected. Fat loss was statistically significant in the arms and legs, but not in the trunk. The above changes were most prominent in the ZDV + 3TC treatment group; in this group of patients, fat loss was also evident in the trunk. Patients on ZDV + ddI, on the other hand, only showed a significant increase in their legs' lean mass; they preserved their total fat mass and exhibited no other significant changes between the two assessments. Conclusions Dual NRTI therapy contributes to fat loss and reduction of bone mineral content in otherwise healthy, clinically stable, PI‐naive HIV‐infected adults. Compared with patients on ZDV + ddI, patients on ZDV + 3TC had a more prominent fat loss in all body regions.Keywords
This publication has 19 references indexed in Scilit:
- Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicityClinical Therapeutics, 2000
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998
- Antiretroviral Therapy for HIV Infection in 1997JAMA, 1997
- Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panelPublished by American Medical Association (AMA) ,1997
- Validation of a dual energy X-ray absorptiometer: measurement of bone mass and soft tissue compositionEuropean Journal of Applied Physiology, 1997
- Assessment of whole-body composition with dual-energy x-ray absorptiometry.Radiology, 1992